Full Press Release Details
Lizama BN, Pandey K, Duong D, et al. CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease . Poster presented at AD/PD 2025 ; Vienna, Austria
CGTX Positive Sentiment
CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease
Key Takeaway: The Phase 2 study SHINE presented findings on the S2R modulator CT1812's effects in Alzheimer's disease. The study utilized CSF proteomic biomarker analysis to identify these effects. The results were showcased at the AD/PD 2025 conference in Vienna, Austria, highlighting the potential of CT1812 in Alzheimer's research.
Price reaction · baseline $0.4208 (2025-03-31 close) · hit pre-market · 4 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.8%
day 1
-1.9%
day 3 · peak
-15.8%
Market Sentiment Analysis
POSITIVE FACTORS
- Identification of effects of CT1812 in Alzheimer's disease.
- Successful presentation of findings at a notable conference.
- Potential for further research and development in Alzheimer's treatment.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Frequently Asked Questions
What is the SHINE study about?
The SHINE study is a Phase 2 trial investigating the effects of the S2R modulator CT1812 in Alzheimer's disease.
Where was the SHINE study presented?
The findings from the SHINE study were presented at the AD/PD 2025 conference in Vienna, Austria.
What type of analysis was used in the SHINE study?
CSF proteomic biomarker analysis was utilized to identify the effects of CT1812.
What is CT1812?
CT1812 is an S2R modulator being studied for its potential effects on Alzheimer's disease.